The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis.
 
Gaetan Des Guetz
No Relationships to Disclose
 
Thierry Landre
No Relationships to Disclose
 
Patrick Nicolas
No Relationships to Disclose
 
Alain Vergnenegre
No Relationships to Disclose
 
Christos Chouaid
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Lilly; Roche